CellaVision（C26）株式概要CellaVision AB（publish）は、血液・体液分析用の機器、ソフトウェア、試薬を開発し、スウェーデン国内外に販売している。 詳細C26 ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長3/6過去の実績2/6財務の健全性6/6配当金4/6報酬当社が推定した公正価値より45%で取引されている 収益は年間18.99%増加すると予測されています アナリストらは、株価が22.4%上昇するだろうとほぼ一致している。 リスク分析不安定な配当実績 すべてのリスクチェックを見るC26 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW490,283 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA490,283 investors already sharing narrativesYour Fair Value€Current Price€12.2422.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture01b2016201920222025202620282031Revenue SEK 1.2bEarnings SEK 202.9mAdvancedSet Fair ValueView all narrativesCellaVision AB (publ) 競合他社Eckert & ZieglerSymbol: XTRA:EUZMarket cap: €856.7mDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.6bCarl Zeiss MeditecSymbol: XTRA:AFXMarket cap: €2.5bOttobock SE KGaASymbol: XTRA:OBCKMarket cap: €3.6b価格と性能株価の高値、安値、推移の概要CellaVision過去の株価現在の株価SEK 12.2452週高値SEK 17.0652週安値SEK 10.64ベータ0.961ヶ月の変化-0.49%3ヶ月変化7.37%1年変化-23.40%3年間の変化-35.51%5年間の変化-73.50%IPOからの変化-52.44%最新ニュースReported Earnings • Jul 19Second quarter 2026 earnings released: EPS: kr1.37 (vs kr1.58 in 2Q 2025)Second quarter 2026 results: EPS: kr1.37 (down from kr1.58 in 2Q 2025). Revenue: kr199.9m (up 4.5% from 2Q 2025). Net income: kr32.6m (down 13% from 2Q 2025). Profit margin: 16% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €13.84, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 3.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.57 per share.Recent Insider Transactions • Jun 12Founder & Director recently bought €1.5m worth of stockOn the 9th of June, Christer Fahraeus bought around 125k shares on-market at roughly €11.73 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.9m. Christer has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares.お知らせ • Apr 29CellaVision AB (Publ) Announces Board AppointmentsCellaVision AB (publ) at its Annual General Meeting held on April 28, 2026 resolved the election of Zlatko Rihter as new Board member. Zlatko Rihter was elected as the new Chairman of the Board of Directors.お知らせ • Apr 24+ 1 more updateCellaVision AB (publ) to Report First Half, 2026 Results on Jul 17, 2026CellaVision AB (publ) announced that they will report first half, 2026 results on Jul 17, 2026お知らせ • Apr 17CellaVision AB (publ) Announces Louise Armstrong-Denby and Mikael Worning Declines Re-ElectionCellaVision AB (publ) announced that Louise Armstrong-Denby has declined re-election; Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member.最新情報をもっと見るRecent updatesReported Earnings • Jul 19Second quarter 2026 earnings released: EPS: kr1.37 (vs kr1.58 in 2Q 2025)Second quarter 2026 results: EPS: kr1.37 (down from kr1.58 in 2Q 2025). Revenue: kr199.9m (up 4.5% from 2Q 2025). Net income: kr32.6m (down 13% from 2Q 2025). Profit margin: 16% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €13.84, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 3.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.57 per share.Recent Insider Transactions • Jun 12Founder & Director recently bought €1.5m worth of stockOn the 9th of June, Christer Fahraeus bought around 125k shares on-market at roughly €11.73 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.9m. Christer has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares.お知らせ • Apr 29CellaVision AB (Publ) Announces Board AppointmentsCellaVision AB (publ) at its Annual General Meeting held on April 28, 2026 resolved the election of Zlatko Rihter as new Board member. Zlatko Rihter was elected as the new Chairman of the Board of Directors.お知らせ • Apr 24+ 1 more updateCellaVision AB (publ) to Report First Half, 2026 Results on Jul 17, 2026CellaVision AB (publ) announced that they will report first half, 2026 results on Jul 17, 2026お知らせ • Apr 17CellaVision AB (publ) Announces Louise Armstrong-Denby and Mikael Worning Declines Re-ElectionCellaVision AB (publ) announced that Louise Armstrong-Denby has declined re-election; Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member.お知らせ • Apr 10CellaVision AB (publ) to Report Q1, 2026 Results on Apr 24, 2026CellaVision AB (publ) announced that they will report Q1, 2026 results at 7:20 AM, Central European Standard Time on Apr 24, 2026お知らせ • Feb 06CellaVision AB (publ) announces Annual dividend, payable on May 06, 2026CellaVision AB (publ) announced Annual dividend of SEK 2.7500 per share payable on May 06, 2026, ex-date on April 29, 2026 and record date on April 30, 2026.お知らせ • Oct 22CellaVision AB (publ), Annual General Meeting, Apr 28, 2026CellaVision AB (publ), Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: lund Swedenお知らせ • May 07+ 1 more updateCellaVision AB (publ) Approves Dividend, Expects to Be Distributed by Euroclear Sweden AB on 13 May 2025CellaVision AB (publ) at the AGM held on 06 May 2025, approved dividend of SEK 2.50 per share with record date on 8 May 2025. The dividend is expected to be distributed by Euroclear Sweden AB on 13 May 2025.お知らせ • Feb 06+ 3 more updatesCellaVision AB (publ) to Report Fiscal Year 2025 Results on Feb 05, 2026CellaVision AB (publ) announced that they will report fiscal year 2025 results on Feb 05, 2026Valuation Update With 7 Day Price Move • Nov 01Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €19.88, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €27.77 per share.お知らせ • Oct 31CellaVision AB (publ), Annual General Meeting, May 06, 2025CellaVision AB (publ), Annual General Meeting, May 06, 2025, at 15:00 W. Europe Standard Time. Location: lund SwedenBuy Or Sell Opportunity • Oct 28Now 21% undervaluedOver the last 90 days, the stock has risen 4.0% to €21.95. The fair value is estimated to be €27.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 57% in the next 2 years.Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: kr1.30 (vs kr1.09 in 3Q 2023)Third quarter 2024 results: EPS: kr1.30 (up from kr1.09 in 3Q 2023). Revenue: kr178.7m (up 6.4% from 3Q 2023). Net income: kr31.1m (up 20% from 3Q 2023). Profit margin: 17% (up from 16% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 01Founder & Director recently sold €2.4m worth of stockOn the 27th of August, Christer Fahraeus sold around 100k shares on-market at roughly €24.10 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.Buy Or Sell Opportunity • Jul 22Now 24% undervaluedOver the last 90 days, the stock has risen 5.5% to €20.95. The fair value is estimated to be €27.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Earnings per share has grown by 4.2%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 61% in the next 2 years.Reported Earnings • Jul 22Second quarter 2024 earnings released: EPS: kr1.62 (vs kr1.46 in 2Q 2023)Second quarter 2024 results: EPS: kr1.62 (up from kr1.46 in 2Q 2023). Revenue: kr187.8m (up 11% from 2Q 2023). Net income: kr38.5m (up 11% from 2Q 2023). Profit margin: 21% (in line with 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jul 02Now 24% undervaluedOver the last 90 days, the stock has risen 7.9% to €21.85. The fair value is estimated to be €28.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years.Buy Or Sell Opportunity • Jun 27Now 21% undervaluedOver the last 90 days, the stock has risen 8.3% to €22.25. The fair value is estimated to be €28.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years.Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €22.65, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.46 per share.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)First quarter 2024 results: EPS: kr1.26 (up from kr0.81 in 1Q 2023). Revenue: kr170.1m (up 22% from 1Q 2023). Net income: kr30.1m (up 57% from 1Q 2023). Profit margin: 18% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 14Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Feb 24Now 20% undervaluedOver the last 90 days, the stock has risen 48% to €22.40. The fair value is estimated to be €28.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.Buy Or Sell Opportunity • Feb 13Now 21% undervaluedOver the last 90 days, the stock has risen 51% to €21.20. The fair value is estimated to be €26.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.Declared Dividend • Feb 09Dividend of kr2.25 announcedShareholders will receive a dividend of kr2.25. Ex-date: 6th May 2024 Payment date: 13th May 2024 Dividend yield will be 9.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (41% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 19% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 83% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 08Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 32%After last week's 32% share price gain to €23.50, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.37 per share.Buy Or Sell Opportunity • Jan 26Now 25% undervaluedOver the last 90 days, the stock has risen 53% to €16.08. The fair value is estimated to be €21.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.Buying Opportunity • Dec 01Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 8.1%. The fair value is estimated to be €19.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. Revenue is forecast to grow by 31% in 2 years. Earnings is forecast to grow by 60% in the next 2 years.Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €12.48, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.01 per share.Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: kr1.09 (vs kr0.43 in 3Q 2022)Third quarter 2023 results: EPS: kr1.09 (up from kr0.43 in 3Q 2022). Revenue: kr167.9m (up 19% from 3Q 2022). Net income: kr26.0m (up 150% from 3Q 2022). Profit margin: 16% (up from 7.4% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • Oct 26+ 5 more updatesCellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024CellaVision AB (publ) announced that they will report nine months, 2024 results on Oct 24, 2024お知らせ • Oct 11CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023CellaVision AB (publ) announced that they will report Q3, 2023 results at 7:20 AM, Central European Standard Time on Oct 25, 2023Buying Opportunity • Sep 14Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 20%. The fair value is estimated to be €17.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 8.4%. Revenue is forecast to grow by 33% in 2 years. Earnings is forecast to grow by 95% in the next 2 years.Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: kr1.46 (vs kr1.56 in 2Q 2022)Second quarter 2023 results: EPS: kr1.46 (down from kr1.56 in 2Q 2022). Revenue: kr169.7m (down 7.6% from 2Q 2022). Net income: kr34.7m (down 6.8% from 2Q 2022). Profit margin: 21% (in line with 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Jul 07CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023CellaVision AB (publ) announced that they will report Q2, 2023 results at 7:20 AM, Central European Standard Time on Jul 20, 2023New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Jun 19Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €14.96, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.46 per share.お知らせ • May 06+ 1 more updateCellavision AB (Publ) Approves Dividend, Payable on May 12, 2023CellaVision AB (publ) in its AGM held on May 5, 2023 approved the proposal on a dividend of SEK 2.25 per share with record date on 9 May 2023. The dividend is expected to be paid by Euroclear Sweden AB on 12 May 2023.Upcoming Dividend • May 01Upcoming dividend of kr2.25 per share at 1.3% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 12 May 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (1.6%).Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €15.28, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.51 per share.Reported Earnings • Apr 16Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Buying Opportunity • Mar 14Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €21.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.Buying Opportunity • Feb 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 9.3%. The fair value is estimated to be €23.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.Reported Earnings • Feb 09Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Buying Opportunity • Feb 09Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €22.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 17%.お知らせ • Feb 08Cellavision AB (Publ) Proposes Dividend for 2022The Board of Directors of CellaVision AB (publ) proposed an increased dividend to SEK 2.25 per share for 2022 (SEK 2.00 per share).Buying Opportunity • Jan 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 30%. The fair value is estimated to be €23.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 20% per annum over the same time period.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to €23.45, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 29x in the Medical Equipment industry in Europe. Total loss to shareholders of 22% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.85 per share.お知らせ • Nov 26+ 1 more updateCellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination CommitteeCellaVision AB (publ) announced that Emil Hjalmarsson has been appointed Chairman of the Nomination Committee. The Nomination Committee consists of: Christer Fåhraeus, Christer Fåhraeus with Companies; Nicklas Hansen, William Demant Invest A/S; Anette Andersson, SEB Investment funds and Emil Hjalmarsson, Grenlunden CEVI AB.Valuation Update With 7 Day Price Move • Nov 02Investor sentiment deteriorated over the past weekAfter last week's 26% share price decline to €18.60, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €26.36 per share.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: kr0.43 (vs kr1.09 in 3Q 2021)Third quarter 2022 results: EPS: kr0.43 (down from kr1.09 in 3Q 2021). Revenue: kr141.0m (up 6.9% from 3Q 2021). Net income: kr10.4m (down 60% from 3Q 2021). Profit margin: 7.4% (down from 20% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 15% share price gain to €27.90, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 9.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.00 per share.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €23.15, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.91 per share.お知らせ • Jul 28CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology LaboratoriesOn July 27, 2022, CellaVision® announces the launch of DIFF-Line TM by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago. DIFF-Line TM by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox. CellaVision® DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision® DC-1 was launched in 2019 and received FDA clearance in October 2020. RAL® SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market now July 27, 2022. RAL® StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL® StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.Reported Earnings • Jul 21Second quarter 2022 earnings released: EPS: kr1.56 (vs kr1.30 in 2Q 2021)Second quarter 2022 results: EPS: kr1.56 (up from kr1.30 in 2Q 2021). Revenue: kr183.6m (up 36% from 2Q 2021). Net income: kr37.3m (up 20% from 2Q 2021). Profit margin: 20% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 10%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • May 12+ 1 more updateCellavision AB (Publ) Announces Dividend, Payable on 18 May 2022CellaVision AB (publ) announced that the AGM held on 11 May 2022 resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 2 per share with record date on 13 May 2022. The dividend is expected to be paid by Euroclear Sweden AB on 18 May 2022.Reported Earnings • May 11First quarter 2022 earnings released: EPS: kr1.61 (vs kr1.19 in 1Q 2021)First quarter 2022 results: EPS: kr1.61 (up from kr1.19 in 1Q 2021). Revenue: kr162.4m (up 21% from 1Q 2021). Net income: kr38.4m (up 35% from 1Q 2021). Profit margin: 24% (up from 21% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • May 05Upcoming dividend of kr2.00 per shareEligible shareholders must have bought the stock before 12 May 2022. Payment date: 18 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (1.2%).Reported Earnings • Apr 23Full year 2021 earnings released: EPS: kr5.26 (vs kr3.75 in FY 2020)Full year 2021 results: EPS: kr5.26 (up from kr3.75 in FY 2020). Revenue: kr565.6m (up 20% from FY 2020). Net income: kr125.3m (up 40% from FY 2020). Profit margin: 22% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 3% per year.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to €29.78, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total returns to shareholders of 5.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €31.82 per share.お知らせ • Feb 06Cellavision AB (Publ) Proposes Dividend for 2021The Board of Directors of CellaVision AB (publ) proposed a dividend of SEK 2.00 per share for 2021 as compared to SEK 0.75 per share a year ago.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to €31.86, the stock trades at a forward P/E ratio of 56x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.88 per share.Reported Earnings • Oct 23Third quarter 2021 earnings released: EPS kr1.09 (vs kr0.56 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr132.0m (up 50% from 3Q 2020). Net income: kr26.1m (up 96% from 3Q 2020). Profit margin: 20% (up from 15% in 3Q 2020). The increase in margin was driven by higher revenue.Recent Insider Transactions • Aug 25Founder & Director recently sold €1.1m worth of stockOn the 23rd of August, Christer Fahraeus sold around 24k shares on-market at roughly €45.43 per share. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.Reported Earnings • Jul 22Second quarter 2021 earnings released: EPS kr1.30 (vs kr1.14 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: kr135.5m (up 15% from 2Q 2020). Net income: kr31.0m (up 14% from 2Q 2020). Profit margin: 23% (in line with 2Q 2020).Executive Departure • May 04Independent Chairman of the Board Sören Mellstig has left the companyOn the 29th of April, Sören Mellstig's tenure in the role of Independent Chairman of the Board ended. As of December 2020, Sören personally held 42.94k shares (€1.3m worth at the time). A total of 2 executives have left over the last 12 months.お知らせ • Apr 30CellaVision AB (publ) Approves Dividend, Payable on 6 May 2021The AGM of CellaVision AB (publ) resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 0.75 per share, with record date 3 May 2021. The dividend is expected to be paid by Euroclear Sweden AB on 6 May 2021.Upcoming Dividend • Apr 24Upcoming dividend of kr0.75 per shareEligible shareholders must have bought the stock before 30 April 2021. Payment date: 06 May 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (1.0%).Reported Earnings • Apr 11Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses.Analyst Estimate Surprise Post Earnings • Feb 06Revenue misses expectationsRevenue missed analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 23%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.Reported Earnings • Feb 06Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Jan 22New 90-day high: €32.02The company is up 11% from its price of €28.88 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €31.95 per share.お知らせ • Dec 02+ 1 more updateCellaVision Announces Executive ChangesThe Board of Directors at CellaVision has appointed Simon Østergaard as President. Simon Østergaard takes on his new role in March 2021, succeeding Zlatko Rihter, who left the company on November 28. Until the date of entry, Magnus Blixt continues in his role as acting CEO and then returns to his regular role as CFO. Simon Østergaard has extensive international experience from the medical device and diagnostic (IVD) industries while holding various leadership positions covering the entire value chain from business development, research & development, quality assurance, operations to sales and marketing. Simon Østergaard joins CellaVision from Agilent Technologies where he holds the role as Vice President & General Manager for the global Pathology Division and the role as Country General Manager for Denmark. In Simon Østergaard's most recent assignment as Vice President & General Manager of the Pathology Division at Agilent Technologies, Simon Østergaard is leading its global franchise for cancer diagnostics with employees located in Copenhagen, Santa Clara, Carpinteria and Penang in addition to the global sales footprint.Is New 90 Day High Low • Oct 29New 90-day low: €27.24The company is down 5.0% from its price of €28.80 on 30 July 2020. The German market is also down 5.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.69 per share.Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 16% share price decline to kr27.84, the stock is trading at a trailing P/E ratio of 77.3x, down from the previous P/E ratio of 92.2x. This compares to an average P/E of 56x in the Medical Equipment industry in Germany. Total returns to shareholders over the past year are 9.6%.お知らせ • Oct 15Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision ABThe Nomination Committee of CellaVision AB announced that the Chairman of the Board, Sören Mellstig, has declined re-election at the 2021 Annual General Meeting.Is New 90 Day High Low • Oct 01New 90-day high: €33.86The company is up 26% from its price of €26.78 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €27.15 per share.株主還元C26DE Medical EquipmentDE 市場7D-7.6%0.1%1.3%1Y-23.4%-26.7%0.9%株主還元を見る業界別リターン: C26過去 1 年間で-26.7 % の収益を上げたGerman Medical Equipment業界を上回りました。リターン対市場: C26は、過去 1 年間で0.9 % のリターンを上げたGerman市場を下回りました。価格変動Is C26's price volatile compared to industry and market?C26 volatilityC26 Average Weekly Movement7.9%Medical Equipment Industry Average Movement5.1%Market Average Movement5.3%10% most volatile stocks in DE Market12.6%10% least volatile stocks in DE Market2.7%安定した株価: C26 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: C26の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1994251Steve Fergusonwww.cellavision.comCellaVision AB (publish)は、血液・体液分析用の機器、ソフトウェア、試薬を開発し、スウェーデン国内外に販売している。同社はデジタル血液顕微鏡ソリューションを提供しており、分析装置、機器、ハードウェア製品には検査室向けの体外診断用医薬品（IVD）、スメアメーカー、ステイナー、染色、染色プロトコールなどがある。DIFF-Lineは毎日少量の血液サンプルを扱う血液検査室で、末梢血塗抹標本の塗抹、染色、分析用の3つの機器CellaVision DC-1、RAL SmearBox、RAL StainBoxで構成されている。CellaVision DM1200とCellaVision DM9600は血液と体液の鑑別の自動化と簡素化のために設計されている。さらに、CellaVision Peripheral Bloodアプリケーションは末梢血塗抹標本などの形態学的検査を自動化、標準化、簡素化することができます；CellaVision CellAtlasは、細胞形態学入門のための広範な細胞画像ライブラリに関する一連のミニ講義のための形態学の専門家によるアプリです。CellaVision Remote Review Softwareは、塗抹標本レビュープロセスから制限的な地理的制約を取り除き、より良いパフォーマンスを実現します。同社は病院と商業検査室に製品を販売している。同社は1994年に設立され、スウェーデンのルンドに本社を置いている。もっと見るCellaVision AB (publ) 基礎のまとめCellaVision の収益と売上を時価総額と比較するとどうか。C26 基礎統計学時価総額€311.92m収益（TTM）€11.69m売上高(TTM)€66.94m26.7xPER（株価収益率4.7xP/SレシオC26 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計C26 損益計算書（TTM）収益SEK 739.15m売上原価SEK 231.28m売上総利益SEK 507.87mその他の費用SEK 378.78m収益SEK 129.09m直近の収益報告Jun 30, 2026次回決算日Oct 29, 2026一株当たり利益（EPS）5.41グロス・マージン68.71%純利益率17.46%有利子負債／自己資本比率5.9%C26 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.9%現在の配当利回り51%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/28 03:09終値2026/07/28 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CellaVision AB (publ) 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Bjorn RydellABG Sundal Collier SponsoredCarl-Oscar BredengenBerenbergKristofer Liljeberg-SvenssonCarnegie Investment Bank AB4 その他のアナリストを表示
Reported Earnings • Jul 19Second quarter 2026 earnings released: EPS: kr1.37 (vs kr1.58 in 2Q 2025)Second quarter 2026 results: EPS: kr1.37 (down from kr1.58 in 2Q 2025). Revenue: kr199.9m (up 4.5% from 2Q 2025). Net income: kr32.6m (down 13% from 2Q 2025). Profit margin: 16% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €13.84, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 3.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.57 per share.
Recent Insider Transactions • Jun 12Founder & Director recently bought €1.5m worth of stockOn the 9th of June, Christer Fahraeus bought around 125k shares on-market at roughly €11.73 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.9m. Christer has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares.
お知らせ • Apr 29CellaVision AB (Publ) Announces Board AppointmentsCellaVision AB (publ) at its Annual General Meeting held on April 28, 2026 resolved the election of Zlatko Rihter as new Board member. Zlatko Rihter was elected as the new Chairman of the Board of Directors.
お知らせ • Apr 24+ 1 more updateCellaVision AB (publ) to Report First Half, 2026 Results on Jul 17, 2026CellaVision AB (publ) announced that they will report first half, 2026 results on Jul 17, 2026
お知らせ • Apr 17CellaVision AB (publ) Announces Louise Armstrong-Denby and Mikael Worning Declines Re-ElectionCellaVision AB (publ) announced that Louise Armstrong-Denby has declined re-election; Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member.
Reported Earnings • Jul 19Second quarter 2026 earnings released: EPS: kr1.37 (vs kr1.58 in 2Q 2025)Second quarter 2026 results: EPS: kr1.37 (down from kr1.58 in 2Q 2025). Revenue: kr199.9m (up 4.5% from 2Q 2025). Net income: kr32.6m (down 13% from 2Q 2025). Profit margin: 16% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €13.84, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 3.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.57 per share.
Recent Insider Transactions • Jun 12Founder & Director recently bought €1.5m worth of stockOn the 9th of June, Christer Fahraeus bought around 125k shares on-market at roughly €11.73 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.9m. Christer has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares.
お知らせ • Apr 29CellaVision AB (Publ) Announces Board AppointmentsCellaVision AB (publ) at its Annual General Meeting held on April 28, 2026 resolved the election of Zlatko Rihter as new Board member. Zlatko Rihter was elected as the new Chairman of the Board of Directors.
お知らせ • Apr 24+ 1 more updateCellaVision AB (publ) to Report First Half, 2026 Results on Jul 17, 2026CellaVision AB (publ) announced that they will report first half, 2026 results on Jul 17, 2026
お知らせ • Apr 17CellaVision AB (publ) Announces Louise Armstrong-Denby and Mikael Worning Declines Re-ElectionCellaVision AB (publ) announced that Louise Armstrong-Denby has declined re-election; Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member.
お知らせ • Apr 10CellaVision AB (publ) to Report Q1, 2026 Results on Apr 24, 2026CellaVision AB (publ) announced that they will report Q1, 2026 results at 7:20 AM, Central European Standard Time on Apr 24, 2026
お知らせ • Feb 06CellaVision AB (publ) announces Annual dividend, payable on May 06, 2026CellaVision AB (publ) announced Annual dividend of SEK 2.7500 per share payable on May 06, 2026, ex-date on April 29, 2026 and record date on April 30, 2026.
お知らせ • Oct 22CellaVision AB (publ), Annual General Meeting, Apr 28, 2026CellaVision AB (publ), Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: lund Sweden
お知らせ • May 07+ 1 more updateCellaVision AB (publ) Approves Dividend, Expects to Be Distributed by Euroclear Sweden AB on 13 May 2025CellaVision AB (publ) at the AGM held on 06 May 2025, approved dividend of SEK 2.50 per share with record date on 8 May 2025. The dividend is expected to be distributed by Euroclear Sweden AB on 13 May 2025.
お知らせ • Feb 06+ 3 more updatesCellaVision AB (publ) to Report Fiscal Year 2025 Results on Feb 05, 2026CellaVision AB (publ) announced that they will report fiscal year 2025 results on Feb 05, 2026
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €19.88, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €27.77 per share.
お知らせ • Oct 31CellaVision AB (publ), Annual General Meeting, May 06, 2025CellaVision AB (publ), Annual General Meeting, May 06, 2025, at 15:00 W. Europe Standard Time. Location: lund Sweden
Buy Or Sell Opportunity • Oct 28Now 21% undervaluedOver the last 90 days, the stock has risen 4.0% to €21.95. The fair value is estimated to be €27.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 57% in the next 2 years.
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: kr1.30 (vs kr1.09 in 3Q 2023)Third quarter 2024 results: EPS: kr1.30 (up from kr1.09 in 3Q 2023). Revenue: kr178.7m (up 6.4% from 3Q 2023). Net income: kr31.1m (up 20% from 3Q 2023). Profit margin: 17% (up from 16% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 01Founder & Director recently sold €2.4m worth of stockOn the 27th of August, Christer Fahraeus sold around 100k shares on-market at roughly €24.10 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.
Buy Or Sell Opportunity • Jul 22Now 24% undervaluedOver the last 90 days, the stock has risen 5.5% to €20.95. The fair value is estimated to be €27.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Earnings per share has grown by 4.2%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 61% in the next 2 years.
Reported Earnings • Jul 22Second quarter 2024 earnings released: EPS: kr1.62 (vs kr1.46 in 2Q 2023)Second quarter 2024 results: EPS: kr1.62 (up from kr1.46 in 2Q 2023). Revenue: kr187.8m (up 11% from 2Q 2023). Net income: kr38.5m (up 11% from 2Q 2023). Profit margin: 21% (in line with 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jul 02Now 24% undervaluedOver the last 90 days, the stock has risen 7.9% to €21.85. The fair value is estimated to be €28.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years.
Buy Or Sell Opportunity • Jun 27Now 21% undervaluedOver the last 90 days, the stock has risen 8.3% to €22.25. The fair value is estimated to be €28.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €22.65, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.46 per share.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)First quarter 2024 results: EPS: kr1.26 (up from kr0.81 in 1Q 2023). Revenue: kr170.1m (up 22% from 1Q 2023). Net income: kr30.1m (up 57% from 1Q 2023). Profit margin: 18% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 14Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Feb 24Now 20% undervaluedOver the last 90 days, the stock has risen 48% to €22.40. The fair value is estimated to be €28.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
Buy Or Sell Opportunity • Feb 13Now 21% undervaluedOver the last 90 days, the stock has risen 51% to €21.20. The fair value is estimated to be €26.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
Declared Dividend • Feb 09Dividend of kr2.25 announcedShareholders will receive a dividend of kr2.25. Ex-date: 6th May 2024 Payment date: 13th May 2024 Dividend yield will be 9.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (41% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 19% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 83% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 08Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 32%After last week's 32% share price gain to €23.50, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.37 per share.
Buy Or Sell Opportunity • Jan 26Now 25% undervaluedOver the last 90 days, the stock has risen 53% to €16.08. The fair value is estimated to be €21.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
Buying Opportunity • Dec 01Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 8.1%. The fair value is estimated to be €19.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. Revenue is forecast to grow by 31% in 2 years. Earnings is forecast to grow by 60% in the next 2 years.
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €12.48, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.01 per share.
Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: kr1.09 (vs kr0.43 in 3Q 2022)Third quarter 2023 results: EPS: kr1.09 (up from kr0.43 in 3Q 2022). Revenue: kr167.9m (up 19% from 3Q 2022). Net income: kr26.0m (up 150% from 3Q 2022). Profit margin: 16% (up from 7.4% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Oct 26+ 5 more updatesCellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024CellaVision AB (publ) announced that they will report nine months, 2024 results on Oct 24, 2024
お知らせ • Oct 11CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023CellaVision AB (publ) announced that they will report Q3, 2023 results at 7:20 AM, Central European Standard Time on Oct 25, 2023
Buying Opportunity • Sep 14Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 20%. The fair value is estimated to be €17.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 8.4%. Revenue is forecast to grow by 33% in 2 years. Earnings is forecast to grow by 95% in the next 2 years.
Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: kr1.46 (vs kr1.56 in 2Q 2022)Second quarter 2023 results: EPS: kr1.46 (down from kr1.56 in 2Q 2022). Revenue: kr169.7m (down 7.6% from 2Q 2022). Net income: kr34.7m (down 6.8% from 2Q 2022). Profit margin: 21% (in line with 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Jul 07CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023CellaVision AB (publ) announced that they will report Q2, 2023 results at 7:20 AM, Central European Standard Time on Jul 20, 2023
New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €14.96, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.46 per share.
お知らせ • May 06+ 1 more updateCellavision AB (Publ) Approves Dividend, Payable on May 12, 2023CellaVision AB (publ) in its AGM held on May 5, 2023 approved the proposal on a dividend of SEK 2.25 per share with record date on 9 May 2023. The dividend is expected to be paid by Euroclear Sweden AB on 12 May 2023.
Upcoming Dividend • May 01Upcoming dividend of kr2.25 per share at 1.3% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 12 May 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (1.6%).
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €15.28, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.51 per share.
Reported Earnings • Apr 16Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Buying Opportunity • Mar 14Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €21.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.
Buying Opportunity • Feb 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 9.3%. The fair value is estimated to be €23.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.
Reported Earnings • Feb 09Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Buying Opportunity • Feb 09Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €22.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 17%.
お知らせ • Feb 08Cellavision AB (Publ) Proposes Dividend for 2022The Board of Directors of CellaVision AB (publ) proposed an increased dividend to SEK 2.25 per share for 2022 (SEK 2.00 per share).
Buying Opportunity • Jan 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 30%. The fair value is estimated to be €23.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 20% per annum over the same time period.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to €23.45, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 29x in the Medical Equipment industry in Europe. Total loss to shareholders of 22% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.85 per share.
お知らせ • Nov 26+ 1 more updateCellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination CommitteeCellaVision AB (publ) announced that Emil Hjalmarsson has been appointed Chairman of the Nomination Committee. The Nomination Committee consists of: Christer Fåhraeus, Christer Fåhraeus with Companies; Nicklas Hansen, William Demant Invest A/S; Anette Andersson, SEB Investment funds and Emil Hjalmarsson, Grenlunden CEVI AB.
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment deteriorated over the past weekAfter last week's 26% share price decline to €18.60, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €26.36 per share.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: kr0.43 (vs kr1.09 in 3Q 2021)Third quarter 2022 results: EPS: kr0.43 (down from kr1.09 in 3Q 2021). Revenue: kr141.0m (up 6.9% from 3Q 2021). Net income: kr10.4m (down 60% from 3Q 2021). Profit margin: 7.4% (down from 20% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 15% share price gain to €27.90, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 9.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.00 per share.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €23.15, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.91 per share.
お知らせ • Jul 28CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology LaboratoriesOn July 27, 2022, CellaVision® announces the launch of DIFF-Line TM by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago. DIFF-Line TM by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox. CellaVision® DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision® DC-1 was launched in 2019 and received FDA clearance in October 2020. RAL® SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market now July 27, 2022. RAL® StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL® StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.
Reported Earnings • Jul 21Second quarter 2022 earnings released: EPS: kr1.56 (vs kr1.30 in 2Q 2021)Second quarter 2022 results: EPS: kr1.56 (up from kr1.30 in 2Q 2021). Revenue: kr183.6m (up 36% from 2Q 2021). Net income: kr37.3m (up 20% from 2Q 2021). Profit margin: 20% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 10%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • May 12+ 1 more updateCellavision AB (Publ) Announces Dividend, Payable on 18 May 2022CellaVision AB (publ) announced that the AGM held on 11 May 2022 resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 2 per share with record date on 13 May 2022. The dividend is expected to be paid by Euroclear Sweden AB on 18 May 2022.
Reported Earnings • May 11First quarter 2022 earnings released: EPS: kr1.61 (vs kr1.19 in 1Q 2021)First quarter 2022 results: EPS: kr1.61 (up from kr1.19 in 1Q 2021). Revenue: kr162.4m (up 21% from 1Q 2021). Net income: kr38.4m (up 35% from 1Q 2021). Profit margin: 24% (up from 21% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • May 05Upcoming dividend of kr2.00 per shareEligible shareholders must have bought the stock before 12 May 2022. Payment date: 18 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (1.2%).
Reported Earnings • Apr 23Full year 2021 earnings released: EPS: kr5.26 (vs kr3.75 in FY 2020)Full year 2021 results: EPS: kr5.26 (up from kr3.75 in FY 2020). Revenue: kr565.6m (up 20% from FY 2020). Net income: kr125.3m (up 40% from FY 2020). Profit margin: 22% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 3% per year.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to €29.78, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total returns to shareholders of 5.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €31.82 per share.
お知らせ • Feb 06Cellavision AB (Publ) Proposes Dividend for 2021The Board of Directors of CellaVision AB (publ) proposed a dividend of SEK 2.00 per share for 2021 as compared to SEK 0.75 per share a year ago.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to €31.86, the stock trades at a forward P/E ratio of 56x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.88 per share.
Reported Earnings • Oct 23Third quarter 2021 earnings released: EPS kr1.09 (vs kr0.56 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr132.0m (up 50% from 3Q 2020). Net income: kr26.1m (up 96% from 3Q 2020). Profit margin: 20% (up from 15% in 3Q 2020). The increase in margin was driven by higher revenue.
Recent Insider Transactions • Aug 25Founder & Director recently sold €1.1m worth of stockOn the 23rd of August, Christer Fahraeus sold around 24k shares on-market at roughly €45.43 per share. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.
Reported Earnings • Jul 22Second quarter 2021 earnings released: EPS kr1.30 (vs kr1.14 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: kr135.5m (up 15% from 2Q 2020). Net income: kr31.0m (up 14% from 2Q 2020). Profit margin: 23% (in line with 2Q 2020).
Executive Departure • May 04Independent Chairman of the Board Sören Mellstig has left the companyOn the 29th of April, Sören Mellstig's tenure in the role of Independent Chairman of the Board ended. As of December 2020, Sören personally held 42.94k shares (€1.3m worth at the time). A total of 2 executives have left over the last 12 months.
お知らせ • Apr 30CellaVision AB (publ) Approves Dividend, Payable on 6 May 2021The AGM of CellaVision AB (publ) resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 0.75 per share, with record date 3 May 2021. The dividend is expected to be paid by Euroclear Sweden AB on 6 May 2021.
Upcoming Dividend • Apr 24Upcoming dividend of kr0.75 per shareEligible shareholders must have bought the stock before 30 April 2021. Payment date: 06 May 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (1.0%).
Reported Earnings • Apr 11Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses.
Analyst Estimate Surprise Post Earnings • Feb 06Revenue misses expectationsRevenue missed analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 23%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.
Reported Earnings • Feb 06Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Jan 22New 90-day high: €32.02The company is up 11% from its price of €28.88 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €31.95 per share.
お知らせ • Dec 02+ 1 more updateCellaVision Announces Executive ChangesThe Board of Directors at CellaVision has appointed Simon Østergaard as President. Simon Østergaard takes on his new role in March 2021, succeeding Zlatko Rihter, who left the company on November 28. Until the date of entry, Magnus Blixt continues in his role as acting CEO and then returns to his regular role as CFO. Simon Østergaard has extensive international experience from the medical device and diagnostic (IVD) industries while holding various leadership positions covering the entire value chain from business development, research & development, quality assurance, operations to sales and marketing. Simon Østergaard joins CellaVision from Agilent Technologies where he holds the role as Vice President & General Manager for the global Pathology Division and the role as Country General Manager for Denmark. In Simon Østergaard's most recent assignment as Vice President & General Manager of the Pathology Division at Agilent Technologies, Simon Østergaard is leading its global franchise for cancer diagnostics with employees located in Copenhagen, Santa Clara, Carpinteria and Penang in addition to the global sales footprint.
Is New 90 Day High Low • Oct 29New 90-day low: €27.24The company is down 5.0% from its price of €28.80 on 30 July 2020. The German market is also down 5.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.69 per share.
Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 16% share price decline to kr27.84, the stock is trading at a trailing P/E ratio of 77.3x, down from the previous P/E ratio of 92.2x. This compares to an average P/E of 56x in the Medical Equipment industry in Germany. Total returns to shareholders over the past year are 9.6%.
お知らせ • Oct 15Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision ABThe Nomination Committee of CellaVision AB announced that the Chairman of the Board, Sören Mellstig, has declined re-election at the 2021 Annual General Meeting.
Is New 90 Day High Low • Oct 01New 90-day high: €33.86The company is up 26% from its price of €26.78 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €27.15 per share.
